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The presence of high-risk human papillomavirus, loss of heterozygosity on chromosome 3p and fragile histidine triad gene expression
were assessed as potential markers of cancer and CIN progression in 83 cervical cancers and 74 cervical intraepithelial neoplasia
grade 1 lesions. Human papillomavirus type 16 was an indicator of vascular involvement in cancers. Loss of heterozygosity, especially
in the fragile histidine triad gene intron 5, was an indicator of high-grade tumours, greater tumour depth and lymph node involvement.
Abnormal fragile histidine triad gene expression was more frequent in cervical intraepithelial neoplasia grade 1 lesions with increased
risk of disease progression.
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Cervical cancer is the second most common cancer in women
worldwide and is nearly always associated with one or more of the
human papillomavirus types which have been shown to carry a
high oncogenic risk (HR HPV) (Munoz et al, 2003). Most HR HPV
infections are transient and resolve spontaneously. High-grade
lesions (cancers and cervical intraepithelial neoplasia grades 2 and
3 (CIN2/3)) are more likely to result from persistent infections,
particularly with HPV16 and/or high viral load (Ylitalo et al, 2000).
HR HPV infection represents only one of many events occurring
early in the development of cervical malignancy, however, and
multiple subsequent genomic and epigenomic changes are believed
to be required.
Loss of heterozygosity (LOH) is an early indicator of genomic
instability, which increases the risk of malignancy. In many human
cancers, LOH is frequently observed in the short arm of
chromosome 3 (3p) (Naylor et al, 1987; Hibi et al, 1992; Druck
et al, 1995; Kastury et al, 1996; Li et al, 1997). For cervical
neoplasia, the chromosomal region of particular interest is 3p14.2
because it includes two known HPV16 integration sites (Thorland
et al, 2000; Corbin et al, 2002) as well as the most commonly
disrupted genomic fragile site, FRA3B (Glover and Stein, 1988).
This site is sensitive to environmental carcinogens (Schantz et al,
2000) and is located between intron 3 and intron 7 of a putative
tumour suppressor gene, fragile histidine triad (FHIT), which has
proapoptotic activity (Ji et al, 1999; Sard et al, 1999; Dumon et al,
2001; Roz et al, 2002). One HPV insertion site is located in intron 4
and the other is centromeric to the FHIT gene. The close proximity
of these genetic elements permits genomic events arising from
breaks and improper repair of such breaks in this region to be
readily monitored.
Loss of heterozygosity in 3p and reduced FHIT expression have
been reported in cervical cancer and precancer lesions (Wistuba
et al, 1997; Birrer et al, 1999; Chung et al, 2000; Connolly et al,
2000; Guo et al, 2001; Acevedo et al, 2002) but, because of small
sample numbers or because of differences in the 3p loci selected
for LOH analysis, it is not clear if any regions of 3p are consistently
deleted or if reduction in FHIT protein level is dependent on these
deletions. In most studies, the HR HPV genotyping was also
incomplete. More importantly, the disease outcome associated
with these genomic changes has not been fully investigated. An
understanding of the biological significance of changes in this
chromosomal region could provide additional information rele-
vant to the outcome of cervical lesions.
In this study, we have examined 83 cervical cancers by analysis
of LOH in chromosome 3p and by HPV genotyping to evaluate the
association between these genetic elements and standard histo-
pathological prognostic markers (histology type, histology grade,
depth of tumour invasion, blood vessel involvement and lymph
node involvement) indicative of progressive disease. Genetic
markers with significant associations were then analysed in 74
low-grade CIN1 lesions to see if these markers could predict the
progression of cervical disease.
MATERIALS AND METHODS
Archival paraffin blocks of cervical biopsies and residual cervical
cells after a smear preparation were obtained from 108 unselected
women (mean age 50.9716.3 years) referred to the Queen
Elizabeth Hospital, Gateshead, Tyne and Wear for cervical cancer
treatment. In all, 25 cancers were excluded from the study. Out of
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ythese, 11 were metastases from organs other than the cervix and 14
contained no amplifiable DNA.
A total of 78 archival paraffin blocks of loop biopsies containing
only CIN1 were obtained from women (mean age 33.479.5 years)
referred for colposcopy. Of these, 24 biopsies were from women
who had been referred following a diagnostic punch biopsy
showing CIN2/3. In these cases, all of the CIN2/3 lesion was
presumably contained and removed in the punch biopsy since only
residual CIN1 was found at all levels in the loop biopsy. These
lesions are referred to as CIN1* in the text. Four CIN1 biopsies
contained no amplifiable DNA and were excluded from the study.
Data from the remaining 83 cancers and 74 CIN1 lesions are
included in this report. All histology was read by a consultant
histopathologist.
Staining for microscopy
In all, 10 serial 10mm sections were prepared from each paraffin
block. Section 1 was stained with haematoxylin and eosin (H&E),
section 2 was stained for proliferating cell nuclear antigen (PCNA)
to confirm the proliferative activity of epithelial cells, sections 3
and 6 were stained for FHIT after epitope retrieval, sections 4 and 5
were stained with methyl-green to locate the lesion prior to micro-
dissection and section 10 in CIN1 cases was scraped and used for
HPV testing. For each case, the sections stained with H&E and
PCNA were photographed and stored digitally. The diseased and
normal tissues to be dissected were selected after agreement
between two observers and dissected from the corresponding
methyl-green-stained sections.
All paraffin-embedded sections were dewaxed with xylene and
re-hydrated in graded alcohol and water. For the H&E stain, Gill’s
haematoxylin and eosin Y were used. FHIT immunostaining and
assessment were carried out after epitope retrieval as described
previously (Terry et al, 2002), except that Napthol-AS-BI (Sigma
N-2125) and Fast Red TR (Sigma F-6760) were used as substrate
following the supplier’s instructions (Sigma) and Mayer’s haema-
toxylin (Sigma MSH-1) was used as a counter stain. Loss or
reduction in FHIT protein expression is referred to as ‘abnormal
FHIT’. Proliferating cell nuclear antigen immunostaining was
carried out similarly using mouse anti-PCNA antibody (clone
PC10, Sigma P8825) as the first antibody, alkaline phosphatase-
conjugated goat antimouse IgG antibody (Sigma A3688) as the
second antibody and eosin as the counter stain. The results were
assessed blind.
Microdissection
Sterile double-distilled water was used throughout. Each section
was dewaxed three times with DE-WAX (InnoGenex) for 5min and
washed with 70% ethanol. After soaking in water for 5min, the
section was stained with methyl-green (1%) in water for 1min.
Excess stain was removed by washing with water and excess water
was removed by gentle shaking. While the section was still moist,
normal or diseased tissue was microdissected using a 25G needle
with the help of a dissecting microscope set up inside a tissue
culture hood (Figure 1A). Special care was taken to minimise
contamination with stromal tissue or lymphocytes. Dissected
tissue was resuspended in 20ml T/E containing Tween 20 (1%) and
proteinase K (PK, 1mgml
 1). Digestion was carried out for 96h at
551C with three additions of fresh PK at 24h intervals. PK was
inactivated subsequently at 981C for 10min.
HPV genotyping
DNA extraction from cervical cancer scrapes using PK and
multiplexed type-specific PCR (mts-PCR) for 13 HR HPV types
were carried out as described previously (Borysiewicz et al, 1996;
Terry et al, 2002).
To determine HPV genotypes present in CIN1 biopsies, one
section was scraped from the slide, digested with PK as above and
amplified using the SPF primer set which can amplify a partially
conserved 65 base region from at least 39 HPV types including the
HR HPV types (Kleter et al, 1998). The amplicon was purified by
electrophoresis on a low melting point agarose gel, followed by
solubilisation of the agarose with agarase (AgarAce, Promega) and
genotyping by direct sequencing (Cuzick et al, 2000) with a Cy5-
labelled sequencing primer.
Loss of heterozygosity analysis
Normal and cancer tissues microdissected from the same cancer
section were compared. For CIN1 sections, epithelial cells from the
PCNA-positive abnormal area adjacent to the squamo-columnar
junction were compared with normal squamous epithelium. Two
sections did not contain normal squamous epithelium and in these
cases normal glandular epithelium was used as the control. Loss of
heterozygosity at 30 3p loci was analysed in cancers using
microsatellite (MS) or single-nucleotide polymorphism (SNP)
markers. The chromosome locations of these markers are taken
from the Human Genome Assembly version hg16 (July 2003). A
combination of MS and SNP analyses allows LOH to be localised
and validated.
Microsatellite (MS) A total of 13 MS loci were analysed in cancers
(Table 1) but, since the number of cells from CIN1 lesions was
Figure 1 Paraffin-embedded sections of a FHIT-positive, PCNA-positive
CIN1 lesion (A, B, C, D), a well-differentiated FHIT-positive cancer (E, F)
and a poorly differentiated FHIT-negative cancer (G, H); stained with
methyl green and microdissected (A), for FHIT protein (B, E, G), for
PCNA (C) and with H&E (D, F, H).
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yTable 1 Chromosome locations of MS and SNP loci analysed on 3p and the frequency of allelic loss (FAL) in 83 cancers
FAL
Name Type XY
Chromosome
location (nucelotides
from 3pter) Region
Chromosome
band
Primer
pool MS SNP
rs718558 GA 1469483 D3S1297, near CNTN6, contactin 6 3p26.3 2
D3S1297 1913402 LOC391505, similar to 60S ribosomal protein
L21
3p26.3 T 17
Rs1024147 GT 2709207 D3S1297, near CNTN4, contactin 4 3p26.3 18
Rs2012053 CG 2941128 D3S1297, near CNTN4, contactin 4 3p26.2 15
D3S1304 6794241 MRPS, 36P1, mitochondria ribosomal protein
S36 pseudogene
3p26.1 A 12
D3S1286 15694136 KIAA0379 KIAA0379 protein 3p25.1 T 5
Rs721624 GA 21625656 D3S1293, FLJ22419, hypothetical protein 3p24.3 5
D3S1293 21802013 FLJ22419, hypothetical FLJ22419 protein 3p24.3 F 2
D3S1266 27832335 Near EOMES eomesdermin homolog (Xenopus
laevis)
3p24.1 D 23
Rs934328 CT 30682709 TGFBR2 TGFB receptor 2 3p24.1 0
Rs877572 CG 30701397 TGFBR2 TGFB receptor 2 3p24.1 18
D3S1211 31041792 Near LOC339896 hypothetical protein 3p24.1 T 17
D3S1611 36929105 (MLH1 intron
12)
Near MLH1 (60k) 3p22.3 F 32
Rs928813 GT 38489162 D3S1611, ACVR2B, RNA binding motif, s/s
interacting protein
3p22.2 15
Rs1005678 CG 50169301 Near 101F6, RASSF1A, putative tumour
suppressor genes, in SEMA3F, semaphorin 3F
3p21.31 32
D3S1582 54552995 CACNA2D3 Calcium channel voltage dep.
a2d3 subunit
3p14.3 C 3
Rs566884 CT 54699343 D3S1582, CACNA2D3, calcium channel
voltage-dependant a2d3 subunit
3p14.3 5
Rs492234 CG 59714807 (FHIT intron
8)
FHIT Intron 8 3p14.2 13
Rs931322 GA 59883591 (FHIT intron
7)
FHIT Intron 7 3p14.2 17
Rs722070 GA 60069630 (FHIT intron
5)
FHIT Intron 5 3p14.2 26
D3S1300 60367241 (FHIT intron
5)
FHIT Intron 5; near NPCR NPC-related
protein
3p14.2 C 27
Rs2301156 GT 60515020 (FHIT intron
4)
FHIT Intron 4 3p14.2 28
Rs1562522 GA 60891272 (FHIT intron
3)
FHIT Intron 3 3p14.2 26
Rs1001788 CT 61129144 (FHIT intron
2)
FHIT Intron 2 3p14.2 0
D3S1261 68535327 Near LOC151645 prosome, macropain 26S
subunit
3p14.1 D 16
D3S1566 70132371 LOC391543 similar to KIAA1839 protein 3p13 D 8
D3S1284 72824320 Near LOC317753 proteasome 26S non-
ATPase subunit
3p13 F 23
Rs1027833 CT 78584994 LOC51159, ROBO1, roundabout guidance
receptor homologue (Drosophila)
3p12.3 8
D3S1595 85991642 LOC253559 nectin-like protein 3 3p12.1 A 18
Rs1986448 AT 87086700 LOC51159, near POU1F1, POU domain, Pit1,
growth hormone factor 1
3p12.1 16
Table 2 Association of HR HPV genotypes with markers of cancer progression
Statistical analysis
HR HPV genotype Risk marker Grade No. of cancers positive/total 2P OR 95% CI
16 Origin Squamous 37/51 0.022 3.000 1.074–8.388
Differentiation Moderate 31/51 0.025 2.959 1.076–8.292
Vessel involvement 32/51 0.003 4.304 1.508–12.689
Group A (16+
aothers) Differentiation Moderate 36/63 0.042 3.111 0.954–11.081
18 Origin Adenocarcinoma 8/14 o0.001 10.167 2.316–44.760
Only significant associations are shown.
aOther types detected were HPV31, 33, 52 and 58, all of which are members of HPV Group A. HPV18 is classified in Group C.
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one in FHIT intron 5 (D3S1300) and the other 5Mb telomeric to
FHIT (D3S1582). Multiplexed PCR primer pools A, C, D, F and T
were used. Only pool C was used in CIN1 cases. One PCR primer
for each locus was Cy5-labelled. Amplified fragments were
analysed using an ALFexpress sequencer (Pharmacia Biotech)
and MS peaks were quantitated using Fragment Manager software
(Pharmacia Biotech). The areas under the major peaks for each MS
were averaged from three independent amplifications run on
different gels. Loss of heterozygosity was assigned to a cancer or
CIN1 lesion, which showed an allelic ratio reduction of X70%
relative to the corresponding normal control.
Single-nucleotide polymorphisms (SNPs)
In all, 17 SNP loci (Table 1) were amplified in cancer and normal
DNA preparations from each cancer case and analysed by
electrophoresis on 2% agarose gels to confirm successful
amplification. Single-nucleotide polymorphism assays were carried
out using SureScore Genotyping Kits according to the instructions
of the manufacturer (Invitrogen). This test uses a two-channel
ELISA-based assay to identify which of the two possible bases at
the SNP position was added to a captured PCR amplicon in a
single-base primer extension reaction. PCR primers and capture
oligos for each SNP analysed were designed using the on-line
software provided (Invitrogen). Each SNP experiment included 33
test samples, three allelic controls (supplied with the kit), three
heterozygous and six homozygous human DNA controls and one
control negative for human DNA all tested in triplicate. Loss of
heterozygosity was assigned to a cancer sample when the
absorbance ratio (405nm/620nm) differed from the absorbance
ratio for the corresponding normal sample by more than two
standard deviations.
Statistical analysis
Association of molecular and prognostic markers was assessed
using Fisher’s exact test or w
2-test for trend. In the LOH analysis,
the frequency of allelic loss (FAL) at a given marker was calculated
as:-
100 
total number of cancers with LOH
total number of cancers which were informative at that locus
RESULTS
Staining and immunostaining characteristics
Figure 1 shows paraffin sections from one CIN1 lesion (a–d)
and two cervical cancers (e, f, g, h), stained with: methyl-green
after cancer tissue had been removed by microdissection (a),
FHIT antibody (b, e, g), PCNA antibody (c) and H&E (d, f, h).
Sections (b) and (e) are FHIT positive and section (g) is FHIT
negative.
Association with cancer prognostic markers
HR HPV HPV16 was preferentially associated with squamous
carcinoma and HPV18 with adenocarcinoma, respectively
(Table 2). HPV16, but not HPV18, was associated with cancers
showing moderate differentiation and vascular spread. No
correlations between HR HPV status and FHIT protein expression
were found. HR HPV genotypes detected other than HPV16 and
HPV18 were HPV31, 33, 52 and 58. Like HPV16, these are all group
A viruses and the group A viruses taken together also show an
association with moderate differentiation.
LOH
Cancer A
Control A
Cancer B
Allele 1
Allele 2
Control B
Allele 1 Allele 2
0.1                 1                                 10
0.1
10
100
Normal (log abs405 nm/abs620 nm)
Cancer (log abs 405 nm
/abs 620 nm )
A
B
Figure 2 (A) Loss of heterozygosity in cancer A but not in cancer B at
the D3S1300 locus as detected by microsatellite analysis. (B) Loss of
heterozygosity at the rs722070 locus by SNP analysis. Results of a
representative experiment involving 33 test samples. &, Homozygous
cases or heterozygous cases showing no LOH. ’, Five heterozygous cases
showing LOH in the cancer, confirmed by repeat testing. —, Positive
controls for allele 1, allele 2 and alleles 1þ2 (supplied by the manufacturer)
tested in triplicate. m, Nine control samples previously tested and
confirmed to be homozygous or heterozygous at this locus.
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profiles obtained by microsatellite analysis (Figure 2A) and SNP
analysis (Figure 2B). Loss of heterozygosity in 3p can occur over
the entire length of the chromosome (Table 1) and the occurrence
of LOH anywhere within 3p was associated with increasingly poor
histological differentiation and with increased depth of invasion
(Table 3a). Overall, LOH was found in 57% cancers and the
number of loci lost ranged from 1 to 11 (Figure 3). No significant
association was found between LOH in the MLH1 mismatch repair
gene and markers of cancer progression.
FHIT protein expression Genomic instability in the FHIT gene
was associated with loss of FHIT expression in a total of two loci
out of seven examined, both located within in intron 5 (Table 3b).
The loss of FHIT protein expression was not correlated with any of
the markers of cancer progression studied.
Evaluation of HR HPV, 3p LOH and FHIT expression in
CIN1 and CIN1* lesions
A total of 29 CIN1 lesions were positive for HR HPV, of which 10
contained HPV16. The incidences of HPV16, HR HPV as a group
and LOH in and close to FHIT intron 5 were not significantly
different in the two CIN1 categories, but the incidence of abnormal
FHIT protein expression was significantly higher in CIN1* (38 vs
10%) (Tables 4 and 5).
DISCUSSION
In all, 93% of cervical cancers contained HR HPV. HPV16 was
the most common and was detected in 61% cancers overall and
71% of squamous carcinomas. Although HR HPV is known to
be pivotal in the development of cervical cancer, its role in cancer
progression as assessed here for HPV16 against histological
markers was found to be limited to an association with vascular
involvement. HPV16 occurred more frequently in moderately
differentiated cancers and did not show any preference for
adenosquamous carcinoma, a histological type which is usually
poorly differentiated and has a lower 5-year survival rate (Davy
et al, 2003; Farley et al, 2003). In contrast, LOH in 3p was found to
be associated with poor differentiation, increased depth of
invasion and, when the LOH occurred in FHIT intron 3 with
lymph node involvement or in FHIT intron 5 with abnormal FHIT
protein expression (Table 3b). Abnormal FHIT protein expression
was not associated with any of the markers of cancer progression
examined. This suggests that chromosomal instability alone may
be an underlying factor in the histological manifestation of
markers of cancer progression observed.
Table 3 Significant associations between LOH in 3p and markers of cancer progression, HR HPV and FHIT protein expression in 83 cancers: (a) Allelic
loss in any region of 3p; (b) allelic loss at specific 3p loci for cancers informative at that locus calculated
Total Risk marker positive Statistical analysis
LOH site Risk markers No LOH With LOH No LOH With LOH P-value OR 95% CI
(a) For all cancers
Anywhere on 3p Differentiation – well 36 47 6 1 1.00
– moderate 36 47 19 23 7.26
– poor 36 47 11 23 12.55
P-trend¼0.018
Depth X10mm 36 47 14 40 2Pp0.001 8.980 2.848–29.751
(b) For informative cancers only
FHIT intron 3 Lympn node involvement 28 10 5 8 2Po0.001 18.400 2.382–206.044
FHIT intron 5 (SNP) Depth X10mm 28 10 18 10 2P¼0.038
a 1.305–
a
FHIT intron 5 (MS) Depth X10mm 54 20 31 20 2Po0.001
a 3.707–
a
Abnormal FHIT protein 54 20 25 16 2P¼0.017 4.640 1.247–21.169
aCannot be calculated.
0
10
20
30
40
50
60
11 2
No. of 3p loci showing LOH
%
23456789 1 0 1 1
Figure 3 The number of 3p loci with LOH in individual cancers. ’
Group A (including HPV16) & HPV18.
Table 4 Cancer prognostic markers in CIN1 and CIN1* lesions
CIN1 lesions CIN1* lesions
Parameters (n¼50) (n¼24) 2p
HR HPV 5 5 0.277
16 4 2 1.000
18 10 3 0.528
Others
a 31 14 0.803
None
D3S1300 locus 5 4 0.216
LOH 35 10
HET/no LOH
D3S1582 locus 2 3 0.314
LOH 39 16
HET/no LOH
FHIT protein 45 15 0.009
Present
Absent or reduced 5 9
aOther types detected were HPV 6, 11, 18, 30, 31, 45, 52, 53, 56, 58, 66 and 67.
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CIN1 lesions which are likely to progress to more severe grades,
and HR HPV and the FHIT gene are two likely candidates. In this
study, we considered that CIN1* lesions should indicate a greater
potential for progression because there is good evidence to suggest
that co-existing lesions, even when topographically distinct, could
have a common origin and could be under the influence of the
same ‘field’ effect (Larson et al, 1977; Park et al, 1998) and
abnormal FHIT protein expression has been found to occur more
frequently in CIN2/3 lesions co-existing with cancer (Connolly
et al, 2000). Our results show that CIN1 and CIN1* lesions have a
similar incidence of HPV16 or other HR HPV (Table 4) so that the
detection of HR HPV per se may not be sufficient to predict
progression of CIN1. Interestingly, the incidence of abnormal
FHIT protein expression in CIN1* is similar to that reported for
CIN2/3 lesions (Birrer et al, 1999; Connolly et al, 2000; Terry et al,
2002) and it was also correlated with the severity of the initially co-
existing lesion grades (Table 5). If these findings are confirmed by
a larger study, abnormal expression of FHIT protein in either
biopsies (as in this study) or in cervical smears (Vecchione et al,
2001) could represent an additional marker for progressive
potential in CIN1 lesions. Replacement therapy for the FHIT
protein might also be effective in preventing the progression of
CIN1 to higher grade lesions.
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